{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:02:24Z","timestamp":1788048144176,"version":"build-2784847793"},"reference-count":23,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We investigated the prognostic value of pretreatment patient\u2010reported outcomes (PROs) in patients with diffuse large B\u2010cell lymphoma (DLBCL) receiving obinutuzumab\/rituximab plus chemotherapy in the GOYA phase III study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients completed the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ\u2010C30) and the Functional assessment of chronic illness therapy\u2010Lymphoma (FACT\u2013Lym) lymphoma subscale (LYMS) during the study. PRO scales with high prognostic value were identified through Cox regression analyses of overall survival (OS) and progression\u2010free survival (PFS). These scales were evaluated in terms of their additional prognostic value beyond the International Prognostic Index (IPI). A preliminary assessment was performed to evaluate whether the scales provided improved patient\u2010risk stratification beyond IPI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One thousand two hundred and fifty\u2010nine patients with valid pretreatment PRO scales were included in the analyses, and complete pretreatment data were available for 1239\/1414 patients (87.6%). Four PRO scales with high prognostic value were identified: FACT\u2013Lym LYMS and EORTC QLQ\u2010C30 physical functioning, global health status\/quality of life (QoL), and fatigue. All four scales retained significant prognostic value for OS and PFS after IPI adjustment (all\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05). After adjusting for multiple clinical variables (IPI, cell of origin,\n                      <jats:italic>BCL2<\/jats:italic>\n                      status, and total metabolic tumor volume), all four scales retained significant prognostic value (all\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05) for OS. Only the EORTC QLQ\u2010C30 physical functioning scale was significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a00.05) for PFS after adjustment for multiple clinical variables.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large population of patients with DLBCL, pretreatment PROs provided prognostic information for OS and PFS beyond the well\u2010established IPI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.4692","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T19:28:43Z","timestamp":1648150123000},"page":"3312-3322","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patient\u2010reported outcomes provide prognostic information for survival in patients with diffuse large B\u2010cell lymphoma: Analysis of 1239 patients from the\n                    <scp>GOYA<\/scp>\n                    study"],"prefix":"10.1002","volume":"11","author":[{"given":"Huang","family":"Huang","sequence":"first","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Datye","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Fan","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knapp","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nielsen","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Bottos","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-7139","authenticated-orcid":false,"given":"Joseph N.","family":"Paulson","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Trask","sequence":"additional","affiliation":[{"name":"Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-5166","authenticated-orcid":false,"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[{"name":"Data Center and Health Outcomes Research Unit Italian Group for Adult Hematologic Diseases (GIMEMA)  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.10.006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-038257"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-102"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28382"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30656-4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3439"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0348"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.017"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1516-0"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.750.750"},{"key":"e_1_2_9_19_1","article-title":"The development and validation of a measure of health\u2010 related quality of life for non\u2010Hodgkin's lymphoma: the functional assessment of cancer therapy\u2014lymphoma (FACT\u2010Lym)","author":"Hlubocky FJ","year":"2013","journal-title":"Lymphoma"},{"key":"e_1_2_9_20_1","article-title":"Measuring quality of life (QOL) in patients with non\u2010Hodgkin's lymphoma (NHL): the functional assessment of cancer therapy\u2010lymphoma (FACT\u2010LYM)","volume":"14","author":"Webster K","year":"2015","journal-title":"Qual Life Res"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2825"},{"key":"e_1_2_9_23_1","volume-title":"A Language and Environment for Statistical Computing","author":"Computing RFfS","year":"2013"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31193"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:31:52Z","timestamp":1692725512000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/cam4.4692"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4692","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"2021-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}